Reproductive Medicine Associates of New Jersey, Morristown, New Jersey, USA.
Fertil Steril. 2011 Feb;95(2):592-5. doi: 10.1016/j.fertnstert.2010.10.003. Epub 2010 Nov 12.
To evaluate in vitro fertilization (IVF) cycle outcomes in young poor responders treated with a luteal estradiol/gonadotropin-releasing hormone antagonist (E(2)/ANT) protocol versus an oral contraceptive pill microdose leuprolide protocol (OCP-MDL).
Retrospective cohort.
Academic practice.
PATIENT(S): Poor responders: 186 women, aged <35 years undergoing IVF with either E(2)/ANT or OCP-MDL protocols.
INTERVENTION(S): None.
MAIN OUTCOME MEASURE(S): Clinical pregnancies, oocytes retrieved, cancellation rate.
RESULT(S): Patients in the E(2)/ANT group had a greater gonadotropin requirement (71.9 ± 22.2 vs. 57.6 ± 25.7) and lower E(2) level (1,178.6 ± 668 vs. 1,627 ± 889), yet achieved similar numbers of oocytes retrieved and fertilized, and a greater number of embryos transferred (2.3 ± 0.9 vs. 2.0 ± 1.1) with a better mean grade (2.14 ± .06 vs. 2.7 ± 1.8) compared with the OCP/MDL group. The E2/ANT group exhibited a trend toward improved implantation rates (30.5% vs. 21.1%) and ongoing pregnancy rates per started cycle: 44 out of 117 (37%) versus 17 out of 69 (25%).
CONCLUSION(S): Poor responders aged <35 years may be treated with the aggressive E(2)/ANT protocol to improve cycle outcomes. Both protocols remain viable options for this group. Adequately powered, randomized clinical comparison appears justified.
评估在黄体雌激素/促性腺激素释放激素拮抗剂(E(2)/ANT)方案与口服避孕药微剂量亮丙瑞林方案(OCP-MDL)治疗下的年轻低反应者的体外受精(IVF)周期结局。
回顾性队列研究。
学术实践。
低反应者:186 名年龄<35 岁的女性,接受 IVF 治疗,分别采用 E(2)/ANT 或 OCP-MDL 方案。
无。
临床妊娠、卵母细胞采集数、取消率。
E(2)/ANT 组患者的促性腺激素需求更高(71.9±22.2 比 57.6±25.7),E(2)水平更低(1,178.6±668 比 1,627±889),但获得了相似数量的卵母细胞采集和受精,以及更多数量的胚胎移植(2.3±0.9 比 2.0±1.1),并且具有更好的平均等级(2.14±0.06 比 2.7±1.8),与 OCP/MDL 组相比。E2/ANT 组的种植率(30.5%比 21.1%)和每个启动周期的持续妊娠率(117 例中有 44 例[37%],69 例中有 17 例[25%])呈改善趋势。
年龄<35 岁的低反应者可以采用积极的 E(2)/ANT 方案进行治疗,以改善周期结局。这两种方案对于该人群仍然是可行的选择。进行充分的、随机的临床比较似乎是合理的。